response
Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia: A 12-Week, Double-Blind, Placebo-Controlled Trial
Abstract: Evidence linking schizophrenia to alterations in presynaptic dopamine (DA) grows, although treatments to date have largely focused on postsynaptic D2 receptor blockade. This study examined augmenting response in treatment-resistant schizophrenia through the addition of tetrabenazine (TBZ), a presynaptic vesicular monoamine transporter (VMAT2) inhibitor. Participants included 41 outpatients (mean age, 43.5 years) with treatment-refractory schizophrenia, stabilized on their present antipsychotic treatment (clozapine, 73%) for more than 3 months.
Effects of Aripiprazole and the Taq1A Polymorphism in the Dopamine D2 Receptor Gene on the Clinical Response and Plasma Monoamine Metabolites Level During the Acute Phase of Schizophrenia
Abstract: The Taq1A polymorphism in the dopamine D2 receptor (DRD2) gene could be related to the response to antipsychotics. We examined the effects of the Taq1A polymorphism on the plasma monoamine metabolites during the treatment of schizophrenia with aripiprazole, a DRD2 partial agonist. Thirty Japanese patients with schizophrenia were treated with aripiprazole for 6 weeks. We measured plasma levels of homovanillic acid (pHVA) and 3-methoxy-4hydroxyphenylglycol (pMHPG) before and after treatment. The Taq1A polymorphism was genotyped with polymerase chain reaction.
Treating Depression After Initial Treatment Failure: Directly Comparing Switch and Augmenting Strategies in STAR*D
Objective: Augmenting and switching antidepressant medications are the 2 most common next-step strategies for depressed patients failing initial medication treatment.
Response to Nimodipine in Ultradian Bipolar Cycling After Amygdalohippocampectomy
No abstract available
Assessing Response to Stroke Thrombolysis: Validation of 24-Hour Multimodal Magnetic Resonance Imaging [Original Contribution]
Background Imaging is used as a surrogate for clinical outcome in early-phase stroke trials. Assessment of infarct growth earlier than the standard 90 days used for clinical end points may be equally accurate and more practical.
Objective To compare assessment of the effect of reperfusion therapies using 24-hour vs day 90 magnetic resonance imaging.
[Correspondence] An open letter to Michael Ball, Chief Executive of Hospira Pharmaceuticals – Response from Hospira
Hospira shares the concern over improper use of our drugs in US executions. Hospira has long communicated that we do not support the use of any of our products in lethal injections—a use that is clearly outside the licensing approved by the Food and Drug Administration and completely counter to our company vision of advancing wellness. In fact, over the years, Hospira has regularly written to every US state to make clear that we oppose the use of our drugs, including pancuronium bromide, in executions, and we have stated our opposition publicly through the media innumerable times.
Editors' response:.
Tyrer P, Waheed W | |